Stayble receives approval from regulatory authorities to start clinical phase 2b study in The Netherlands

Report this content

Stayble announces today, March 17 2020, that the Dutch regulatory authorities (RA) have approved the Company´s clinical trial application on the clinical phase 2b study with STA363. The approval from the RA is conditioned final approval by the Ethics Committee, which has not yet finalized the review of the application. STA363 is targeting patients suffering from chronic low back pain caused by disc degeneration.

The primary goal of the phase 2b trial is to demonstrate safety, tolerability and a clinically relevant reduction in pain in patients. The study will include about 100 patients and will be conducted at about 20 clinical sites in the Netherlands, Russia and Spain.

CEO Andreas Gerward comments: The approval of our clinical trial application from the Dutch authorities less than two weeks after we submitted the application is an important step towards the start of our clinical phase 2b trial and a great achievement from our team. We are now awaiting the responses from the Russian and Spanish regulatory agencies and working full speed forward with the goal of initiating the study during Q2 2020.

For more information

Andreas Gerward, CEO Stayble Therapeutics AB

+46 730 808 397

About Stayble Therapeutics AB

Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once and the effect is expected to remain throughout the entirety of the patient’s life and to require minimal rehabilitation. The Company’s focus is set upon the continued clinical development of the upcoming clinical phase 2b study. Stayble’s vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain.

Mangold Fondkommission AB is the Company’s Certified Adviser and can be reached at +46 (0)8 503 015 50 or e-mail

The information above was provided by Stayble Therapeutics AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on 17 March 2020 at 7.30pm CET.


Documents & Links